China's First Biotech M&A Deal In 2022 Signals Busy Season Ahead?

 
• By Dexter Jie Yan
  
More and more Chinese Biotechs are teaming up with larger-scale domestic pharma companies for wider market access.
2022's first bolt-on acquisition in China signals a trend worth watching • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia